Clinical trials: Primary Progressive MS
Primary Progressive Multiple Sclerosis
Gray Matter Demyelination in Primary Progressive MS at 7T
Progressive-onset multiple sclerosis (PPMS) occurs in about 15% of all people living with MS. PPMS remains understudied, and most disease-modifying treatments are ineffective for PPMS.
- Trial name
- NCT04977622
- Where
- Denmark
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Danish Research Centre for Magnetic Resonance
Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
ACTH in Progressive Forms of MS
This is a phase II, randomized, double-blind, placebo-controlled, multi-center study to evaluate the safety, tolerability, and efficacy of adrenocorticotropic hormone (ACTH, Acthar gel) administered as a pulsed regimen consisting…
- Conditions
- Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
- Trial name
- NCT01950234
- Testing
- ACTH
- Where
- 3 sites in United States
- Volunteers
- 59 people
- Sponsor
- University of Minnesota
Multiple Sclerosis
MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCV
MAIN STUDY: The purpose of this study is to determine if teriflunomide will be safe and effective to prevent relapses in patients with relapsing types of MS when switching from natalizumab to teriflunomide in patients at risk for…
- Trial name
- NCT01970410
- Testing
- teriflunomide
- Where
- 3 sites in United States
- Volunteers
- 55 people
- Sponsor
- Providence Health & Services
Relapsing Remitting MS, Secondary Progressive MS
Caprylic Triglyceride for Treatment of Cognitive Impairments in Multiple Sclerosis
Background/Rationale: Cognitive problems are a common symptom in individuals with Multiple Sclerosis (MS). Treatment options are limited, and there is a pressing need for new interventions to treat MS-related cognitive…
- Conditions
- Relapsing Remitting MS, Secondary Progressive MS, Primary Progressive MS
- Trial name
- NCT01848327
- Testing
- Caprylic Triglyceride
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- University of Miami
Multiple Sclerosis
Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis
The purpose of this study is to demonstrate the superiority of MD1003 over placebo in the visual improvement of patients suffering from chronic visual loss resulting from multiple sclerosis related optic neuritis.
- Trial name
- MS-ON (NCT02220244)
- Testing
- MD1003 100mg capsule
- Where
- 20 sites in France, United Kingdom
- Volunteers
- 105 people
- Sponsor
- MedDay Pharmaceuticals SA
Primary Progressive Multiple Sclerosis
Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS)
Background: Multiple sclerosis (MS) is an inflammatory disorder of the central nervous system that progressively weakens and destroys the pathways of the nervous system.
- Trial name
- IPPoMS (NCT00950248)
- Testing
- Idebenone
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Multiple Sclerosis, Primary Progressive Multiple Sclerosis
C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis Refractory to Standard Therapy
This is a global, multicenter, Phase 1b/2 study evaluating the safety and efficacy of C-CAR168, an autologous anti-CD20/BCMA chimeric antigen receptor T-cell therapy, in participants with progressive multiple sclerosis refractory…
- Conditions
- Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progress Multiple Sclerosis (SPMS), Primary Progressive Multiple Sclerosis (PPMS)
- Trial name
- NCT07825389
- Testing
- C-CAR168
- Where
- 2 sites in United States
- Volunteers
- 119 people
- Sponsor
- AbelZeta Inc.
Primary Progressive Multiple Sclerosis, Primary Progressive MS
A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)
The goal of this Phase 2 clinical trial is to investigate the safety and tolerability of SUN-627 in men and women aged 18-70 years old with a diagnosis of non-active SPMS/PPMS.
- Conditions
- Primary Progressive Multiple Sclerosis, Primary Progressive MS, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive MS (SPMS)
- Trial name
- NCT07840326
- Testing
- SUN-627
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Sundance Biosciences, Inc.
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
Imaging of Intracerebral Inflammation in MS
In this study we plan to image the compartmentalized inflammation in MS using molecular imaging by positron emission tomography (PET) with a very highly resolutive camera.
- Conditions
- Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive
- Trial name
- INFLASEP (NCT02305264)
- Testing
- 18F-DPA-714 and 18F-FDG
- Where
- 2 sites in France
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis, Primary Progressive
Follow-up Study of the Effectiveness of Virtual Reality Therapy in MS Patients
Different therapies can improve clinical and motor symptoms of multiple sclerosis (MS) similarly, but studies comparing the effects of different exercise therapies on clinical and motor outcomes are scant.
- Trial name
- NCT04550650
- Testing
- Training groupe, PNF, Spinning grp
- Where
- Hungary
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Somogy Megyei Kaposi Mór Teaching Hospital
Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting
Acute Intermittent Hypoxia Combined With Gait Training in Multiple Sclerosis
This interventional, randomized, sham-controlled study will examine whether Acute Intermittent Hypoxia (AIH) delivered immediately before Myoelectric Interface Neurorehabilitation Training (MINT)-based locomotor training improves…
- Conditions
- Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis (MS) Secondary Progressive
- Trial name
- MINT (NCT07631923)
- Testing
- Acute Intermittent Hypoxia (AIH), Myoelectric Interface Neurorehabilitation Training (MINT)
- Volunteers
- 35 people
- Sponsor
- Shirley Ryan AbilityLab
Multiple Sclerosis
Correlation Between Multiple Sclerosis Functional Composite (MSFC) and Expanded Disability Status Scale (EDSS) in Patients With Multiple Sclerosis (MS) in Argentina
This observational study is being conducted to evaluate the usefulness of the MSFC and its relationship with EDSS scores in subjects with MS in Argentina.
- Trial name
- NCT01080014
- Where
- Argentina
- Volunteers
- 252 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis
Safety and Efficacy of S103 Cells in Progressive/Refractory Multiple Sclerosis
This study is a single-center, open-label, single-arm, exploratory clinical study to evaluate the safety, tolerability, and preliminary efficacy of S103（BCMA-CAR T ）cells in the treatment of progressive or refractory multiple…
- Conditions
- Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis, Multiple Sclerosis (MS) Secondary Progressive, Refractory Multiple Sclerosis
- Trial name
- RESET-MS (NCT07587125)
- Testing
- S103 cells
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Xijing Hospital
Primary Progressive Multiple Sclerosis
Intrathecal Administration of DUOC-01 in Adults With Primary Progressive Multiple Sclerosis
This study is a prospective Phase 1a open-label single- center trial. It will assess the safety of intrathecal administration of DUOC-01 cells to adults with Primary Progressive Multiple Sclerosis (PPMS).
- Trial name
- DUOC for MS (NCT04943289)
- Testing
- DUOC-01
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Joanne Kurtzberg, MD
Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Secondary Progressive
A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS
The study is an investigator-run, study following participants for 2 years with twice-daily remibrutinib. MRI is the main endpoint. Safety, tolerability, and efficacy are secondary endpoints.
- Conditions
- Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Secondary Progressive, Multiple Sclerosis (MS) Primary Progressive
- Trial name
- RemiSeven (NCT07222956)
- Testing
- Remibrutinib (Open Label)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Moein Amin
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Chronic Progressive
Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis: A Trans-regional Digital Health Effort Unlocking the Potential of Artificial Intelligence and Data Science in Health Care
The Clinnova-Multiple Sclerosis (MS) study is part of the Clinnova program (NCT06526364; NCT06235684 and NCT05733702), which seeks to advance precision medicine and the digitalization of healthcare through high-quality…
- Conditions
- Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Chronic Progressive, Clinically Isolated Syndrome, Primary Progressive Multiple Sclerosis
- Trial name
- Clinnova-MS (NCT07280871)
- Testing
- Cohort
- Where
- Luxembourg
- Volunteers
- 100 people
- Sponsor
- Luxembourg Institute of Health
Multiple Sclerosis, Primary Progressive Multiple Sclerosis (PPMS)
IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis
This is an open label, Phase 1b, multiple ascending dose, and dose-expansion study of IDP-023 administered in combination with interleukin-2 (IL-2) and ocrelizumab to evaluate the safety, tolerability, and biologic activity on…
- Conditions
- Multiple Sclerosis, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS), Non-Active Secondary Progressive Multiple Sclerosis
- Trial name
- NCT06677710
- Testing
- IDP-023, Ocrelizumab, Interleukin-2
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- Indapta Therapeutics, INC.
Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting
Home Based Functional Balance Intervention for Multiple Sclerosis
The study involves a two-arm, Phase 1, randomized controlled clinical trial designed to establish the feasibility and effects of a Functional Balance Intervention (FBI) on physical and cognitive function, as well as measures of…
- Conditions
- Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis (MS) Secondary Progressive
- Trial name
- HomeFBIinMS (NCT07355387)
- Testing
- Multicomponent balance intervention consisting of four components including dual-tasking, functional strength, vestibular and dynamic balance., Stretching
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Illinois at Chicago
Multiple Sclerosis
PET Study in Multiple Sclerosis
While both conventional and advanced MRI techniques offer important insights into MS pathophysiology, important aspects of this inflammatory disorder are undetectable with existing MRI technology.
- Trial name
- NCT03787446
- Where
- Canada
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
Open-label Study of Liothyronine in MS
This study will evaluate the safety and tolerability of synthetic T3, liothyronine. It will establish if there are changes in MS symptoms and if there is a positive effect on markers of neuronal health.
- Conditions
- Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive
- Trial name
- NCT02506751
- Testing
- liothyronine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Johns Hopkins University